Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Gimatecan in Adults With Recurrent or Progressive Malignant Glioma
NCT00087061Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gimatecan in malignant glioma (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 24 months and Antitumor Activity up to 24 months. Started May 2004; status: completed.
02
Drugs
gimatecan
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00087061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087061.